CG Oncology Inc

CGON

Company Profile

  • Business description

    CG Oncology Inc is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. The company's lead candidate, cretostimogene grenadenorepvec, is a targeted oncolytic intravesically delivered immunotherapy agent that is in two phase three trials (one high-risk BCG unresponsive NMIBC trial and one intermediate-risk NMIBC trial) and a phase two clinical study with a checkpoint inhibitor for high-risk BCG unresponsive NMIBC disease.

  • Contact

    400 Spectrum Center Drive
    Suite 2040
    IrvineCA92618
    USA

    T: +1 949 409-3700

    https://www.cgoncology.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2025

    Employees

    113

Stocks News & Analysis

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,624.906.60-0.08%
CAC 407,788.1038.69-0.49%
DAX 4024,038.19188.30-0.78%
Dow JONES (US)42,098.70244.95-0.58%
FTSE 1008,726.0152.04-0.59%
HKSE23,258.31123.68-0.53%
NASDAQ19,100.9498.22-0.51%
Nikkei 22537,722.401.71-0.00%
NZX 50 Index12,279.9182.35-0.67%
S&P 5005,888.5532.99-0.56%
S&P/ASX 2008,396.9010.70-0.13%
SSE Composite Index3,339.930.76-0.02%

Market Movers